ITCI: Total Utang marang Modal Intra-Cellular

Logo perusahaan publik Intra-Cellular Therapies (ITCI)

Intra-Cellular Therapies (ITCI) generates revenue from the supply of Caplyta to psychiatric centers for the treatment of bipolar disorder and schizophrenia, receiving payments from insurers. The company is pursuing growth through B2B channels in US hospitals and the search for new medical applications for the drug. This chart reflecting the total debt-to-equity ratio at 0.01 highlights the financial profile amid a dependence on a single product and insurance coverage risks.

ITCI - Total Utang marang Modal Intra-Cellular ing rentang 04.07.2022 - 13.04.2025

Rincian metrik lan analitis perusahaan Intra-Cellular Therapies, Inc. (ITCI)

- rega lan prakiraan konsensus rega:
Bagan rega Intra-Cellular Therapies Inc.|ITCI - Prakiraan gabungan firma investasi
- informasi kapitalisasi pasar:
Kapitalisasi pasar Intra-Cellular Therapies|ITCI - Total Nilai Perusahaan
- indikator kapitalisasi buku:
Nilai Akuntansi saben Saham Intra-Cellular Therapies|ITCI - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku intracellulartherapies.com|ITCI - Nilai Agregat Aset
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Intra-Cellular Therapies|ITCI - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal Intra-Cellular Therapies Inc.|ITCI - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Intra-Cellular Therapies|ITCI - Tanggungan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Intra-Cellular Therapies|Likuiditas cepet intracellulartherapies.com
- statistik bathi lan rasio pasar:
ITCI - Bathi pungkasan
Analisis wiwitan perusahaan:ITCI, Intra-Cellular Therapies
Barang utama Intra-Cellular Therapies, Inc.

The stable debt-to-equity ratio of Intra-Cellular Therapies (ITCI) confirms financial resilience as the company expands its list of medical indications and competes for psychiatrist loyalty. This ratio, calculated as total liabilities divided by equity, measures the business's dependence on creditors, where low values minimize default risks amid rising rates and provide a safety buffer for investments in clinical trials.

Perusahaan pesaing

Utang marang Ekuitas Biogen|Rasio Utang marang Ekuitas NBIX (Neurocrine)|Total Utang marang Modal RGC|AXSM - Utang marang Modal|ACADIA Pharmaceuticals - Rasio Total Utang marang Ekuitas|Total Utang marang Modal xenon-pharma.com XENE|VKTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi SUPN (Supernus Pharmaceuticals, Inc.)|Catalyst Pharmaceuticals Inc (CPRX) - Utang marang Ekuitas|Utang marang Modal Denali Corp (DNLI)|HRMY (Harmony Biosciences) - Total Utang marang Modal|biohavenpharma.com (BHVN) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Amylyx Pharmaceuticals, Inc. (AMLX)|Trevi Therapeutics Inc - Rasio Utang marang Ekuitas|Praxis Medicines - Rasio Total Utang marang Ekuitas|Utang Agregat marang Modal AVXL (Anavex Life Sciences Corp)|CBLL - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi PRTA (Prothena Corporation PLC)|ALEC: Total Utang marang Modal|Annexon Biosciences (ANNX) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas OMER|NGNE - Rasio Utang marang Modal|Total Utang marang Modal ACIU|Rasio Total Utang marang Ekuitas voyagertherapeutics.com VYGR|Total Utang marang Modal NMRA (Neumora Therapeutics, Inc.)|Scilex Holding (SCLX) - Utang marang Modal|TVGN - Utang marang Ekuitas|ACOG: Utang marang Ekuitas|Cognition Therapeutics (CGTX) - Utang marang Ekuitas|IKT (inhibikase.com) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas SAVA|Total Utang marang Modal Assertio Therapeutics|Utang marang Ekuitas Coya Therapeutics, Inc. (COYA)|Utang marang Ekuitas VTGN (vistagen.com)|Total Utang marang Modal OVID (Ovid Therapeutics)|Total Utang marang Modal acumenpharm.com ABOS|CRVO - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi ATHE (Alterity Therapeutics)|CLNN (clene.com) - Rasio Total Utang marang Ekuitas|PepGen - Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas JUNS|RLMD (relmada.com) - Utang Agregat marang Modal|Total Utang marang Modal ANVS|GRCE (gracetx.com) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal AIFF (Firefly Neuroscience Inc)|ANEW Medical (KLTO) - Utang marang Modal|NRSN - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi RVPH (revivapharma.com)|MTVA: Total Utang marang Modal|NeurAxis Inc. (NRXS) - Total Utang marang Modal|Utang marang Ekuitas Helius Medical Technologies, Inc.|Passage Bio Corp - Utang Agregat marang Ekuitas|Total Utang marang Modal NEUP|Koefisien Total Utang marang Modal minervaneurosciences.com|Total Utang marang Modal ATHA (Athira Pharma)|Addex Therapeutics Ltd. (ADXN) - Utang marang Modal|ALZN - Utang marang Ekuitas|Koefisien Total Utang marang Modal Cyclerion Therapeutics CYCN|PTIX: Total Utang marang Modal|KTTA - Koefisien Total Utang marang Modal|Rasio Total Utang marang Ekuitas CRGT|ATXI (Avenue Therapeutics Inc.) - Utang Agregat marang Modal|Total Utang marang Modal BCLI|Rasio Total Utang marang Ekuitas Cara Therapeutics Inc CARA|Total Utang marang Modal CHRO (Chromocell Therapeutics)|Koefisien Total Utang marang Modal Eliem Therapeutics, Inc. (ELYM)|LBPH - Utang marang Ekuitas|MRNS (Marinus Pharmaceuticals Inc) - Rasio Utang marang Ekuitas|NKGN: Total Utang marang Modal|Utang marang Modal NeuroBo Pharma (NRBO)|Rasio Total Utang marang Ekuitas SAGE|Total Utang marang Modal synaptogen.com|Utang marang Ekuitas Trevena (TRVN)|VIGL (vigilneuro.com) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Anew Medical WENA|Cerevel Corp (CERE) - Utang marang Modal